NCT06731127 is a clinical trial in HIV Infections, sponsored by University of Toronto.

Who is sponsoring NCT06731127?

NCT06731127 is sponsored by University of Toronto.

What condition does NCT06731127 study?

NCT06731127 studies HIV Infections.

Is NCT06731127 still recruiting?

NCT06731127 is currently completed. Last updated 2 December 2025.

Last reviewed 2025-12-02 · How we verify

NCT06731127

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People With HIV

Completed Last updated 2 December 2025

What this trial tests

trial in HIV Infections in 75 participants. Completed in 1 December 2022.

Timeline

10 April 2021

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	University of Toronto
Status	Completed
Study type	OBSERVATIONAL
Enrollment	75
Start date	10 April 2021
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across Canada

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

University of Toronto

Who can join

55 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, non-randomized observational study to examine SARS-CoV-2 vaccine immunogenicity, immune activation and HIV reservoirs in people with HIV infection in comparison with HIV-negative individuals, in those aged 55 or more. As Canada is currently rolling out COVID-19 vaccines, the two most imminent vaccines are mRNA vaccines. These are the Pfizer-BioNTech COVID-19 vaccine given 3 weeks apart and the Moderna COVID-19 vaccine given 4 weeks apart. Given the unique storage requirements of these vaccines, it is expected that the Moderna vaccine will be used primarily in primary care clinics such as Maple Leaf Medical Clinic, Toronto. However, the protocol will also allow observational study of individuals being administered with the Pfizer-BioNTech vaccine if it is also available. The investigators predict general availability of both vaccines to the primary care population by March 1, 2021. Vaccination will occur as per clinical and public health guidelines. COVID-19 vaccines will not be administered as a part of this research study. This is a single site longitudinal study where 75 participants in total are followed over 48 weeks with blood draws and saliva sampling. The breakdown of study arms is described here: • PWH Immune responders (n= 35): undetectable viral load for 1+ year, CD4 \>500/uL, CD4/CD8 ratio \>1 including individuals with a historical, low CD4 nadir • PWH Immune non-responders (n= 10): undetectable viral load, CD4 \<350/uL or CD4/CD8 ratio \<0.75 for 1+ year • PWH Low-level viremics (n= 10): low-level viremia (\<1,000 copies/mL) for 1+ year, any CD4, any CD4/CD8 ratio • HIV-negative control (n= 20): age and sex matched

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other University of Toronto trials

Trials by the same sponsor.

NCT07184255 — Animated Video Education for Retinal Surgery · NA · not yet recruiting
NCT07259434 — Time Restricted Eating in Survivors Trial 2.0 · NA · not yet recruiting
NCT07486050 — The Impact of Social Worker Referrals on Diabetes and Loneliness · NA · active not recruiting
NCT07268729 — Investigation of Pathogenic Gut Microbiota Patterns in Anxiety, Depression and Panic Disorders · not yet recruiting
NCT07317921 — Validating IAAO for Muscle Outcomes · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06731127 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Toronto
Last refreshed: 2 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06731127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing